Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death

Journal of Gastroenterology

Volumn 40, Issue 5, 2005, Pages 504-510

  Abe, Tamaki ^a,b   Toyota, Minoru ^a,c   Suzuki, Hiromu ^a   Murai, Masafumi ^a   Akino, Kimishige ^a   Ueno, Masako ^a   Nojima, Masanori ^a   Yawata, Atsushi ^a   Miyakawa, Hiroyuki ^b   Suga, Toshihiro ^b   Ito, Hideto ^a   Endo, Takao ^a   Tokino, Takashi ^a   Hinoda, Yuji ^d   Imai, Kohzoh ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; DNA methylation; Epigenetics; Hypoxia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BISULFITE; CASPASE 8; PROTEIN BNIP3;

APOPTOSIS; ARTICLE; ASSOCIATION; CANCER CELL; CELL DEATH; CELL HYPOXIA; CELL LYSATE; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; INCUBATION TIME; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING;

ANOXIA; BASE SEQUENCE; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DEOXYCYTIDINE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE PROTEINS; METHYLATION; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SULFITES; UP-REGULATION;

EID: 20444437669     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-005-1576-1     Document Type: Article

References (36)

1. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004;34:238-44.
2. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78:580-91.
3. Matsukuma S, Suda K. Small pancreatic tubular adenocarcinomas: clinicopathological analysis with immunohistochemical and histochemical evaluation. Pathol Int 1996;46:581-8.
4. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
5. Crino L, Mosconi AM, Calandri C, Corgna E, Porrozzi S, Chiara S, et al. Gemcitabine in advanced pancreatic cancer: A phase II trial. Am J Clin Oncol 2001;24:296-8.
6. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7: 347-53.
7. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
9. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003;162:1283-91.
10. Buchler P, Reber HA, Buchler M, Shrinkante S, Buchler MW, Friess H, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003;26:56-64.
11. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-73.
12. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S, et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2003;23:4721-7.
13. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
14. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 2004;10:2000-6.
15. Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 2002;86:1817-23.
16. Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, et al. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 2003;9:6410-8.
17. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
18. Boyd JM, Malstrom S, Subramanian T, Venkatesh LK, Schaeper U, Elangovan B, et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 1994;79:341-51.
19. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
20. Ueno M, Toyota M, Suzuki H, Akino K, Nojima M, Tokino T, Imai K. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 2003;25:134-40.
21. Walford GA, Moussignac RL, Scribner AW, Loscalzo J, Leopold JA. Hypoxia potentiates nitric oxide-mediated apoptosis in endothelial cells via peroxynitrite-induced activation of mitochondria-dependent and -independent pathways. J Biol Chem 2004;279:4425-32.
22. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003;100:1931-6.
23. Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, et al. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 2001;8:367-76.
24. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10:2299-306.
25. Niizaki H, Kobayashi M, Horiuchi I, Akakura N, Chen J, Wang J, et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 2002;86:1914-9.
26. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
27. Yasuda M, Theodorakis P, Subramanian T, Chinnadurai G. Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence. J Biol Chem 1998;273:12415-21.
28. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC, et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000;275:1439-48.
29. Yasuda M, Han JW, Dionne CA, Boyd JM, Chinnadurai G. BNIP3alpha: A human homolog of mitochondrial proapoptotic protein BNIP3. Cancer Res 1999;59:533-7.
30. Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, et al. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol 2003;201:573-80.
31. Regula KM, Ens K, Kirshenbaum LA. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002;91:226-31.
32. Yamada T, Ohwada S, Saitoh F, Adachi M, Morishita Y, Hozumi M. Induction of Ley antigen by 5-aza-2′-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Anticancer Res 1996;16:735-40.
33. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004;64:5338-46.
34. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61:6548-54.
35. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100: 2957-64.
36. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103: 1635-40.